company background image
JAGSNPHARM logo

Jagsonpal Pharmaceuticals Informe acción NSEI:JAGSNPHARM

Último precio

₹357.20

Capitalización de mercado

₹9.4b

7D

4.0%

1Y

7.1%

Actualizada

05 May, 2024

Datos

Finanzas de la empresa

Jagsonpal Pharmaceuticals Limited

Informe acción NSEI:JAGSNPHARM

Capitalización de mercado: ₹9.4b

Resumen de acción JAGSNPHARM

Jagsonpal Pharmaceuticals Limited se dedica a la fabricación y comercialización de productos farmacéuticos e ingredientes farmacéuticos activos en los ámbitos de la salud femenina, el dolor y los analgésicos, y la medicina general en India y a escala internacional.

JAGSNPHARM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends5/6

Competidores de Jagsonpal Pharmaceuticals Limited

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Jagsonpal Pharmaceuticals
Historical stock prices
Current Share Price₹357.20
52 Week High₹514.85
52 Week Low₹273.60
Beta0.99
1 Month Change14.69%
3 Month Change17.11%
1 Year Change7.12%
3 Year Change267.11%
5 Year Change1,242.86%
Change since IPO-46.92%

Noticias y actualizaciones recientes

Recent updates

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Apr 30
There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Apr 05
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Feb 06
Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jul 29
Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

May 13
A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Jul 05
Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jun 13
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Apr 19
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Mar 21
Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Feb 08
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Jan 08
The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Dec 21
Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30
Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Rentabilidad de los accionistas

JAGSNPHARMIN PharmaceuticalsMercado IN
7D4.0%0.8%0.5%
1Y7.1%58.6%44.7%

Rentabilidad vs. Industria: JAGSNPHARM obtuvo unos resultados inferiores a los del sector Indian Pharmaceuticals , que el año pasado arrojó un rendimiento del 56.7%.

Rentabilidad vs. Mercado: JAGSNPHARM obtuvo unos resultados inferiores a los del mercado Indian, que fue del 46.4% el año pasado.

Volatilidad de los precios

Is JAGSNPHARM's price volatile compared to industry and market?
JAGSNPHARM volatility
JAGSNPHARM Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.7%
10% most volatile stocks in IN Market9.9%
10% least volatile stocks in IN Market4.2%

Precio estable de las acciones: JAGSNPHARM no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de JAGSNPHARM (8%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
1978940Manish Guptawww.jagsonpal.com

Jagsonpal Pharmaceuticals Limited se dedica a la fabricación y comercialización de productos farmacéuticos e ingredientes farmacéuticos activos en los ámbitos de la salud femenina, el dolor y los analgésicos, y la medicina general en India y a escala internacional. Ofrece formulaciones farmacéuticas y medicamentos de venta libre en los ámbitos de la ginecología, la ortopedia y el tratamiento de alergias. Ofrece medicamentos en forma de comprimidos, cápsulas blandas, inyecciones, cápsulas y jarabes.

Resumen de fundamentos de Jagsonpal Pharmaceuticals Limited

¿Cómo se comparan los beneficios e ingresos de Jagsonpal Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de JAGSNPHARM
Capitalización bursátil₹9.44b
Beneficios(TTM)₹245.17m
Ingresos (TTM)₹2.21b

38.5x

Ratio precio-beneficio (PE)

4.3x

Ratio precio-ventas (PS)

¿Está JAGSNPHARM sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de JAGSNPHARM
Ingresos₹2.21b
Coste de los ingresos₹858.09m
Beneficio bruto₹1.35b
Otros gastos₹1.10b
Beneficios₹245.17m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)9.27
Margen bruto61.11%
Margen de beneficio neto11.11%
Ratio deuda/patrimonio5.5%

¿Cómo se ha desempeñado JAGSNPHARM a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.4%

Rentabilidad actual por dividendo

49%

Ratio de pagos